Therapeutic strategies for congenital myasthenic syndromes
To date, more than 25 genes have been implicated in the etiology of the congenital myasthenic syndromes (CMS), and an ever-growing phenotypic landscape is now encountered in the CMS clinic. Unlike the autoimmune form of myasthenia, there is no role for immunomodulatory agents in the treatment of CMS...
Κύριοι συγγραφείς: | Lee, M, Beeson, D, Palace, J |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
Wiley
2018
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
The congenital myasthenic syndromes.
ανά: Palace, J, κ.ά.
Έκδοση: (2008) -
Congenital myasthenic syndromes.
ανά: Beeson, D, κ.ά.
Έκδοση: (1997) -
Congenital myasthenic syndromes: an update.
ανά: Finlayson, S, κ.ά.
Έκδοση: (2013) -
Congenital myasthenic syndromes and the neuromuscular junction.
ανά: Cruz, P, κ.ά.
Έκδοση: (2014) -
The neuromuscular junction and wide heterogeneity of congenital myasthenic syndromes
ανά: Rodríguez Cruz, P, κ.ά.
Έκδοση: (2018)